Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 1/20 | 0.68 |
| ▸ | MMP2 | P08253 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | BTK | Q06187 | 1/20 | 0.33 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.32 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.32 |
| ▸ | FKBP5 | Q13451 | 1/20 | 0.32 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.31 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.31 |
| ▸ | CDK2 | P24941 | 1/20 | 0.31 |
| ▸ | CDK9 | P50750 | 1/20 | 0.31 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.31 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.31 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | TYMP | P19971 | 1/20 | 0.31 |
| ▸ | GSK3B | P49841 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Uracil SCHEMBL18132339 | 0.91 | CRBN (0.57) | CRBNMMP2TP53PDE3BPDE3A | |
| Uracil SCHEMBL7977993 | 0.88 | CRBN (0.68) | CRBNMMP2TP53BTKPDE3B | |
| Uracil SCHEMBL27698159 | 0.86 | CRBN (0.65) | CRBNMMP2TP53BTKPDE3B | |
| Thymine SCHEMBL17144680 | 0.84 | ATAD2 (0.54) | CRBNMMP2TP53MAPTMEN1 | |
| Uracil SCHEMBL27799965 | 0.83 | CRBN (0.90) | CRBNMMP2TP53BTKFKBP5 | |
| Uracil SCHEMBL8235 | 0.82 | — | — | |
| Uracil SCHEMBL5089507 | 0.82 | — | — | |
| Uracil SCHEMBL3798527 | 0.82 | CRBN (1.00) | CRBNMMP2TP53FKBP5MAPT | |
| Uracil SCHEMBL11607890 | 0.82 | — | — | |
| Uracil SCHEMBL28278941 | 0.82 | CRBN (0.59) | CRBNMMP2TP53BTKFKBP5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 312 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12018320-B2 | Selective oxidation of 5-methylcytosine by TET-family proteins | THE CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2024-06-25 | — | — | US | disclosed |
| US-20240197843-A1 | BACTERIA ENGINEERED TO TREAT DISORDERS IN WHICH OXALATE IS DETRIMENTAL | SYNLOGIC OPERATING COMPANY, INC. (US) | 2024-06-20 | — | — | US | disclosed |
| WO-2024129974-A1 | RECOMBINANT BACTERIA FOR USE IN THE TREATMENT OF DISORDERS IN WHICH OXALATE IS DETRIMENTAL | SYNLOGIC OPERATING COMPANY, INC. (US) | 2024-06-20 | — | — | WO | disclosed |
| EP-4384611-A2 | RECOMBINANT BACTERIA ENGINEERED TO TREAT DISEASES ASSOCIATED WITH METHIONINE METABOLISM AND METHODS OF USE THEREOF | Synlogic Operating Company, Inc. (US) | 2024-06-19 | — | — | EP | disclosed |
| US-20240191284-A1 | SELECTIVE OXIDATION OF 5-METHYLCYTOSINE BY TET-FAMILY PROTEINS | THE CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2024-06-13 | — | — | US | disclosed |
| US-20240191176-A1 | BACTERIA ENGINEERED TO SECRETE ACTIVE PROTEINS | SYNLOGIC OPERATING CO INC (US) | 2024-06-13 | — | — | US | disclosed |
| US-20240180974-A1 | MICROORGANISMS PROGRAMMED TO PRODUCE IMMUNE MODULATORS AND ANTI-CANCER THERAPEUTICS IN TUMOR CELLS | SYNLOGIC OPERATING COMPANY, INC. | 2024-06-06 | — | — | US | disclosed |
| US-11993794-B2 | Methods to create chemically-induced dimerizing protein systems for regulation of cellular events | FRED HUTCHINSON CANCER CENTER (US) | 2024-05-28 | — | — | US | disclosed |
| WO-2024081768-A1 | BACTERIA ENGINEERED TO PRODUCE ACTIVE EPIDERMAL GROWTH FACTOR (EGF) AND THEIR MEDICAL USES | SYNLOGIC OPERATING COMPANY, INC. (US) | 2024-04-18 | — | — | WO | disclosed |
| US-20240110192-A1 | BACTERIA ENGINEERED TO TREAT DISEASES THAT BENEFIT FROM REDUCED GUT INFLAMMATION AND/OR TIGHTENED GUT MUCOSAL BARRIER | SYNLOGIC OPERATING COMPANY, INC. (US) | 2024-04-04 | — | — | US | disclosed |
| WO-1996040165-A1 | METHODS OF REDUCING TOXICITY OF CHEMOTHERAPEUTIC AND ANTIVIRAL AGENTS WITH ACYLATED PYRIMIDINE NUCLEOSIDES | PRO-NEURON, INC. (US) | 1996-12-19 | — | — | WO | disclosed |
| US-5541313-A | Single-stranded labelled oligonucleotides of preselected sequence | MOLECULAR BIOSYSTEMS, INC. (US) | 1996-07-30 | — | — | US | disclosed |
| US-5446137-A | Substituent selected from linking group containing modifiers such as biotin, reactive groups, nucleic acids, catalysts, DNA intercalators, minor groove binders, clevage agents, and detectable labels | SYNTEX (U.S.A.) INC. (US) | 1995-08-29 | — | — | US | disclosed |
| WO-1994026761-A1 | TREATMENT OF CHEMOTHERAPEUTIC AGENT AND ANTIVIRAL AGENT TOXICITY WITH ACYLATED PYRIMIDINE NUCLEOSIDES | PRO-NEURON, INC. (US) | 1994-11-24 | — | — | WO | disclosed |
| US-4948882-A | Single-stranded labelled oligonucleotides, reactive monomers and methods of synthesis | SYNGENE, INC. (US) | 1990-08-14 | — | — | US | disclosed |
| EP-0135587-B1 | DEFINED SEQUENCE SINGLE STRAND OLIGONUCLEOTIDES INCORPORATING REPORTER GROUPS, PROCESS FOR THE CHEMICAL SYNTHESIS THEREOF, AND NUCLEOSIDES USEFUL IN SUCH SYNTHESIS | SYNGENE, INC. (US) | 1990-05-02 | — | — | EP | disclosed |
| EP-0135587-A4 | DEFINED SEQUENCE SINGLE STRAND OLIGONUCLEOTIDES INCORPORATING REPORTER GROUPS, PROCESS FOR THE CHEMICAL SYNTHESIS THEREOF, AND NUCLEOSIDES USEFUL IN SUCH SYNTHESIS. | MOLECULAR BIOSYSTEMS INC (US) | 1986-04-02 | — | — | EP | disclosed |
| EP-0135587-A1 | DEFINED SEQUENCE SINGLE STRAND OLIGONUCLEOTIDES INCORPORATING REPORTER GROUPS, PROCESS FOR THE CHEMICAL SYNTHESIS THEREOF, AND NUCLEOSIDES USEFUL IN SUCH SYNTHESIS. | MOLECULAR BIOSYSTEMS INC (US) | 1985-04-03 | — | — | EP | disclosed |
| WO-1984003285-A1 | DEFINED SEQUENCE SINGLE STRAND OLIGONUCLEOTIDES INCORPORATING REPORTER GROUPS, PROCESS FOR THE CHEMICAL SYNTHESIS THEREOF, AND NUCLEOSIDES USEFUL IN SUCH SYNTHESIS | MOLECULAR BIOSYSTEMS INC (US) | 1984-08-30 | — | — | WO | disclosed |
| US-4461619-A | Method of predicting biological activity of compounds by nucleic acid models | MEDICAL COLLEGE OF GEORGIA RESEARCH INST. (US) | 1984-07-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240110192-A1 | BACTERIA ENGINEERED TO TREAT DISEASES THAT BENEFIT FROM REDUCED GUT INFLAMMATION AND/OR TIGHTENED GUT MUCOSAL BARRIER | FABP2, TLR9, LY96 | CRBN 2122/4885MMP2 2430/4885TP53 3522/4885 |
| US-20240180974-A1 | MICROORGANISMS PROGRAMMED TO PRODUCE IMMUNE MODULATORS AND ANTI-CANCER THERAPEUTICS IN TUMOR CELLS | PDCD1, CD274, PDCD4 | CRBN 881/4885MMP2 1335/4885TP53 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.